Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Ovarian Cancer Metastatic × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 15 Lymphoma 15 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Leukemia, Myeloid, Acute 11 Leukemia, Lymphocytic, Chronic, B-Cell 11 Lymphoma, Non-Hodgkin 10 Lymphoma, Follicular 10 Burkitt Lymphoma 10 Multiple Myeloma 9 Lymphoma, Mantle-Cell 9 Leukemia 9 Melanoma 7 Myelodysplastic Syndromes 6 Lymphoma, B-Cell, Marginal Zone 6 Carcinoma, Non-Small-Cell Lung 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5 Lymphoma, Large-Cell, Anaplastic 5 Hodgkin Disease 5 Hematologic Neoplasms 5 Triple Negative Breast Neoplasms 4 Sezary Syndrome 4 Sarcoma 4 Ovarian Neoplasms 4 Mycosis Fungoides 4 Lymphoma, T-Cell, Cutaneous 4 Lymphoma, Large-Cell, Immunoblastic 4 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Waldenstrom Macroglobulinemia 3 Neoplasm Metastasis 3

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡